SARS-CoV-2 vaccine (Curapath/Afrigen Biologics)

N/A

Report date: 2025/01/26 17:04:31

Base Information

Drug NameSARS-CoV-2 vaccine (Curapath/Afrigen Biologics)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth AfricaSpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPolypeptide Therapeutic Solutions SL
China Registration ClassN/A

Develop Information

Active CompaniesPolypeptide Therapeutic Solutions SLAfrigen Biologics and Vaccines
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A